PT-141 (Bremelanotide): Mechanism, Research & Scientific Overview

Key Points

• PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II
• Molecular formula: C50H68N14O10 with a molecular weight of 1,025.2 g/mol
• Primary mechanism involves activation of melanocortin-4 receptors (MC4R) in the central nervous system
• FDA approved as Vyleesi (bremelanotide injection) in June 2019 for hypoactive sexual desire disorder in premenopausal women
• Research PT-141 remains a distinct compound used in preclinical investigations of melanocortin system biology

Table of Contents

1. Introduction
2. Molecular Structure
3. Mechanism of Action
4. Clinical Development History
5. Research Overview
6. Safety Profile
7. Comparison to PDE5 Inhibitors
8. Research Limitations
9. Conclusion
10. References

Introduction

PT-141, known by its International Nonproprietary Name (INN) as bremelanotide, represents a significant advancement in melanocortin peptide research. This cyclic heptapeptide emerged from investigations into the broader melanocortin system, specifically as a metabolite and structural derivative of Melanotan II (MT-II), another synthetic melanocortin analog that was initially developed for tanning applications.

The melanocortin system comprises a family of peptide hormones and their corresponding receptors (MC1R through MC5R) that regulate diverse physiological processes including pigmentation, energy homeostasis, immune function, and sexual behavior. Alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring tridecapeptide derived from proopiomelanocortin (POMC), serves as the endogenous ligand for these receptors. Early research into synthetic melanocortin analogs focused primarily on developing compounds with enhanced potency and selectivity for specific receptor subtypes.

PT-141 distinguishes itself from its parent compound Melanotan II through its lack of the C-terminal amide group, resulting in a metabolically distinct compound with a different receptor binding profile. While Melanotan II exhibits broad activity across multiple melanocortin receptors, PT-141 demonstrates relatively selective activity at MC3R and MC4R, with the latter being primarily responsible for its documented effects on sexual function.

The clinical development of PT-141 culminated in the FDA approval of Vyleesi (bremelanotide injection) in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval marked the first melanocortin-based therapy for sexual dysfunction and validated decades of research into the central mechanisms governing sexual arousal.

Important Distinction: This article addresses both the FDA-approved pharmaceutical product (Vyleesi/bremelanotide) and research-grade PT-141. While chemically identical, these exist in different regulatory contexts. Vyleesi is a prescription medication subject to FDA oversight, while research PT-141 refers to the compound used in laboratory settings for scientific investigation. All clinical information pertains to the approved pharmaceutical formulation.

Molecular Structure

Chemical Properties

Structural Characteristics

PT-141 is characterized by its cyclic heptapeptide structure, formed through a lactam bridge between the side chains of aspartic acid and lysine residues. This cyclization confers enhanced metabolic stability compared to linear peptides while maintaining the conformational requirements for melanocortin receptor binding.

The peptide sequence begins with an acetylated norleucine (Nle) residue at the N-terminus, which replaces the methionine found in native alpha-MSH, providing improved oxidative stability. The presence of D-phenylalanine (D-Phe) in position 7 (relative to the alpha-MSH numbering) is critical for receptor binding and distinguishes synthetic melanocortin analogs from endogenous peptides.

The core pharmacophore of PT-141 contains the His-D-Phe-Arg-Trp tetrapeptide sequence, which is essential for melanocortin receptor recognition. This sequence corresponds to positions 6-9 of alpha-MSH and represents the minimum structural requirement for receptor activation across the melanocortin receptor family.

Relationship to Melanotan II

PT-141 is structurally derived from Melanotan II through a simple chemical modification. Melanotan II possesses the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a C-terminal amide group. PT-141 lacks this C-terminal amide, instead terminating as a free carboxylic acid (-OH).

This seemingly minor modification results in measurable differences in receptor binding and biological activity:

• Reduced MC1R affinity: PT-141 shows decreased activity at the MC1R pigmentation receptor compared to Melanotan II
• Preserved MC4R activity: Central nervous system effects mediated through MC4R remain intact
• Modified pharmacokinetics: The free carboxylic acid affects distribution and elimination profiles
• Distinct metabolic pathways: Different susceptibility to peptidase-mediated degradation

The development of PT-141 from Melanotan II exemplifies rational peptide drug design, where structural modifications are employed to optimize target selectivity and minimize off-target effects.

Mechanism of Action

Melanocortin Receptor Family

The melanocortin receptor system comprises five G protein-coupled receptors (MC1R through MC5R), each with distinct tissue distributions and physiological functions:

MC4R Activation and CNS Effects

The primary mechanism underlying PT-141's documented effects on sexual function involves activation of melanocortin-4 receptors (MC4R) in the central nervous system. MC4R is predominantly expressed in hypothalamic nuclei, including the paraventricular nucleus (PVN), arcuate nucleus, and lateral hypothalamic area, as well as in brainstem regions and the spinal cord.

MC4R activation by PT-141 initiates a signaling cascade involving:

1. G-protein coupling: MC4R couples primarily to Gs proteins, leading to adenylyl cyclase activation
2. cAMP production: Increased intracellular cyclic AMP (cAMP) levels activate protein kinase A (PKA)
3. Downstream signaling: PKA phosphorylates various substrates affecting neuronal excitability and neurotransmitter release
4. Oxytocin release: MC4R activation in the PVN stimulates oxytocin-producing neurons
5. Descending pathways: Central effects are transmitted to peripheral targets via autonomic pathways

Research has demonstrated that MC4R knockout mice fail to display the sexual arousal responses observed in wild-type animals following melanocortin agonist administration, confirming the receptor's essential role in this pathway.

Oxytocin System Integration

A critical aspect of PT-141's mechanism involves the hypothalamic oxytocin system. Studies have established that:

• MC4R is expressed on oxytocin-synthesizing neurons in the paraventricular nucleus
• Melanocortin agonists increase oxytocin release into both systemic circulation and the central nervous system
• Oxytocin antagonists can attenuate the pro-erectile effects of melanocortin agonists in animal models
• The oxytocinergic projection to the spinal cord appears to mediate peripheral physiological responses

This integration with the oxytocin system distinguishes melanocortin-based approaches from peripheral vasodilator mechanisms employed by PDE5 inhibitors.

MC3R Contribution

While MC4R receives primary emphasis, PT-141 also activates melanocortin-3 receptors (MC3R). MC3R is expressed in hypothalamic regions and peripheral tissues, with documented roles in:

• Energy homeostasis and feeding behavior
• Cardiovascular regulation
• Inflammatory responses

The relative contribution of MC3R versus MC4R activation to PT-141's overall biological effects remains an active area of investigation. Some researchers propose that MC3R may play a modulatory role, while others suggest tissue-specific effects depending on receptor expression patterns.

Peripheral versus Central Mechanisms

Unlike peripheral vasodilators, PT-141 operates primarily through central nervous system mechanisms:

Central Mechanism (PT-141):

• Requires intact hypothalamic-pituitary axis
• Effects modulated by psychological state and context
• Produces both physiological and subjective arousal responses
• Independent of local blood flow effects

Peripheral Mechanism (PDE5 Inhibitors):

• Acts directly on vascular smooth muscle
• Requires intact nitric oxide signaling
• Primarily affects erectile hemodynamics
• Limited effect on subjective desire

This mechanistic distinction has implications for both efficacy and the patient populations that may benefit from each approach.

Clinical Development History

Early Research Phase (1990s-2000s)

The development trajectory of PT-141 began with research into Melanotan II at the University of Arizona in the 1980s and 1990s. Initial observations of sexual side effects during pigmentation studies prompted systematic investigation of melanocortin agonists for sexual dysfunction.

Key early milestones included:

• 1996: Initial reports of melanocortin-induced erections in human subjects during tanning research
• 1998: Systematic preclinical studies demonstrating MC4R involvement in sexual function
• 2000: Palatin Technologies acquires development rights to PT-141

Phase I and II Trials (2001-2008)

Early clinical development focused on establishing safety, pharmacokinetics, and preliminary efficacy:

Phase I Studies:

• Demonstrated acceptable safety profile in healthy volunteers
• Established subcutaneous administration as preferred route
• Characterized dose-response relationships
• Identified nausea as primary dose-limiting adverse event

Phase II Studies:

• Showed efficacy in erectile dysfunction patients unresponsive to sildenafil
• Demonstrated effects in female sexual dysfunction populations
• Established proof-of-concept for central mechanism
• Refined dosing parameters

A notable intranasal formulation was evaluated but encountered regulatory concerns regarding blood pressure effects, leading to abandonment of this route.

Phase III Development (2014-2019)

Palatin Technologies (in partnership with AMAG Pharmaceuticals) conducted pivotal Phase III trials focusing on hypoactive sexual desire disorder in premenopausal women:

RECONNECT Studies:

• Randomized, double-blind, placebo-controlled design
• Enrollment of over 1,247 premenopausal women with HSDD
• Primary endpoint: Female Sexual Function Index (FSFI) desire domain score
• Secondary endpoints: Satisfying sexual events, distress measures

Key Findings:

• Statistically significant improvement in FSFI desire domain scores
• Increased number of satisfying sexual events compared to placebo
• Reduced distress associated with low sexual desire
• Treatment effect observed across multiple patient subgroups

FDA Approval (June 2019)

On June 21, 2019, the FDA approved Vyleesi (bremelanotide injection) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. Key approval parameters included:

• Indication: HSDD in premenopausal women (acquired, generalized subtype)
• Formulation: 1.75 mg subcutaneous injection via autoinjector
• Dosing: On-demand, at least 45 minutes before anticipated sexual activity
• Frequency limit: Maximum once every 24 hours, no more than 8 doses per month
• Contraindications: Uncontrolled hypertension, cardiovascular disease

The approval represented the first melanocortin-based therapy for any indication and validated decades of research into central mechanisms of sexual function.

Post-Marketing Status

Since approval, Vyleesi has been available by prescription in the United States. Post-marketing surveillance continues to monitor:

• Long-term safety data
• Real-world efficacy patterns
• Adverse event reporting
• Utilization patterns in clinical practice

Research Overview

Sexual Function Studies

The most extensive body of PT-141 research addresses sexual function across various contexts:

Male Erectile Function:

• Phase II studies demonstrated efficacy in erectile dysfunction populations
• Particularly notable responses in patients with psychological/mixed etiology
• Some efficacy observed in PDE5 inhibitor non-responders
• Clinical development in male populations was not pursued to approval

Female Sexual Dysfunction:

• Pivotal Phase III trials established efficacy in HSDD
• Effects on both desire and arousal components documented
• Improvements in distress and relationship satisfaction measures
• Basis for FDA approval of Vyleesi

Mechanistic Studies:

• Neuroimaging research demonstrates hypothalamic activation
• Oxytocin release confirmed in human subjects
• Central arousal distinct from peripheral hemodynamic effects
• Context-dependent response patterns observed

Melanocortin System Research

PT-141 serves as a pharmacological tool for investigating melanocortin receptor biology:

Receptor Selectivity Studies:

• Binding affinity comparisons across MC1R-MC5R
• Structure-activity relationships with related analogs
• Receptor desensitization and internalization patterns
• Cross-talk between melanocortin receptor subtypes

Neuroanatomical Mapping:

• Identification of responsive brain regions via fMRI
• Characterization of descending autonomic pathways
• Integration with other neuroendocrine systems
• Sex differences in melanocortin circuit organization

Cardiovascular Effects

Research has characterized PT-141's cardiovascular profile:

Observed Effects:

• Transient increases in blood pressure (particularly with intranasal administration)
• Modest effects on heart rate
• Generally reversible hemodynamic changes
• Basis for cardiovascular contraindications in product labeling

Mechanistic Investigations:

• Role of MC3R/MC4R in cardiovascular regulation
• Central versus peripheral contributions
• Relationship to sympathetic nervous system activation
• Impact of route of administration

Pigmentation Research

While PT-141 shows reduced MC1R activity compared to Melanotan II, some pigmentation research has been conducted:

• Lower potency for melanogenesis induction
• Reduced tanning effects compared to parent compound
• Mechanistic studies of MC1R binding requirements
• Implications for photobiology and UV protection

Safety Profile

Clinical Trial Safety Data

Safety data from Phase III clinical trials (Vyleesi approval studies) characterized the following profile:

Common Adverse Events (>5% incidence):

Notable Safety Findings:

• Nausea was the most common adverse event, typically mild-to-moderate
• Most adverse events were transient, resolving within hours
• No serious adverse events attributed to study drug in pivotal trials
• Tachyphylaxis to nausea observed with repeated dosing

Blood Pressure Considerations

Cardiovascular effects represent an important safety consideration:

• Transient blood pressure elevations observed, particularly with higher doses
• Mean increases generally under 10 mmHg systolic
• Effects typically resolved within 12 hours
• Led to contraindication in uncontrolled hypertension
• Cardiovascular disease listed as contraindication

Hyperpigmentation

Focal hyperpigmentation has been reported:

• Darkening of face, gingiva, and breasts observed in some patients
• Generally reversible upon discontinuation
• Related to residual MC1R activity
• Monitoring recommended during treatment

Use Restrictions

Based on safety data, product labeling includes specific restrictions:

• Maximum 8 doses per month
• Minimum 24-hour interval between doses
• Contraindicated in uncontrolled hypertension
• Contraindicated in cardiovascular disease
• Not recommended in hepatic or renal impairment (limited data)

Comparison with Preclinical Safety

Animal toxicology studies supported clinical development:

• No evidence of carcinogenicity in standard assays
• No effects on fertility in reproductive toxicology studies
• Reversible effects consistent with pharmacology
• Adequate safety margins for clinical dosing

Comparison to PDE5 Inhibitors

Mechanistic Differences

PT-141 and PDE5 inhibitors (sildenafil, tadalafil, vardenafil) operate through fundamentally different mechanisms:

Clinical Implications

These mechanistic differences have practical implications:

PT-141 May Be Preferred When:

• Psychological or mixed etiology dysfunction
• Desire component is primary concern
• PDE5 inhibitor non-response or contraindication
• Central nervous system-mediated arousal is desired

PDE5 Inhibitors May Be Preferred When:

• Vascular etiology is established
• Predictable, reliable onset is needed
• Central nervous system effects are unwanted
• Cardiovascular risk profile is acceptable

Efficacy in Different Populations

Clinical data suggest differential efficacy patterns:

PT-141:

• Efficacy in HSDD (approved indication)
• Phase II efficacy in ED with psychological component
• Potential utility in PDE5 non-responders

PDE5 Inhibitors:

• Well-established efficacy in erectile dysfunction
• Effective across multiple etiologies
• Extensive real-world experience

Adverse Event Profiles

Different mechanisms produce distinct adverse event patterns:

Combination Potential

Research has explored potential combination strategies:

• Theoretically complementary mechanisms
• Limited clinical combination data available
• Safety of combination not established
• Regulatory status does not support off-label combinations

Research Limitations

Regulatory and Availability Distinctions

A critical consideration in PT-141 research involves the distinction between:

FDA-Approved Vyleesi:

• Manufactured under GMP conditions
• Regulated pharmaceutical product
• Specific approved indication (HSDD in premenopausal women)
• Prescribed through healthcare providers
• Quality-controlled formulation

Research PT-141:

• Variable manufacturing standards
• Not intended for human use
• Research purposes only
• No regulatory oversight
• Purity and identity not guaranteed

Researchers must be aware that findings from approved pharmaceutical formulations may not directly apply to research-grade materials.

Study Population Limitations

Current clinical evidence has notable population restrictions:

• FDA approval limited to premenopausal women with HSDD
• Male erectile dysfunction studies did not proceed to Phase III
• Limited data in postmenopausal women
• Minimal data in diverse ethnic populations
• Age restrictions in studied populations

Mechanistic Questions

Despite significant research, several mechanistic questions remain:

1. Relative MC3R versus MC4R contributions: The precise balance of receptor involvement requires further characterization

2. Individual response variability: Factors predicting response or non-response are incompletely understood

3. Long-term receptor effects: Extended use effects on melanocortin system sensitivity are unknown

4. Integration with other systems: Full mapping of melanocortin interactions with other neuroendocrine axes continues

Comparison Study Gaps

Head-to-head comparative studies are limited:

• No direct comparison trials with PDE5 inhibitors
• Combination therapy not systematically studied
• Cost-effectiveness analyses limited
• Quality-of-life comparisons incomplete

Preclinical to Clinical Translation

Several observations from preclinical studies require human validation:

• Species differences in melanocortin receptor biology
• Pharmacokinetic translation to human dosing
• Behavioral model relevance to human sexual function
• Long-term safety extrapolations

Conclusion

PT-141 (bremelanotide) represents a significant scientific achievement in melanocortin peptide research and central nervous system pharmacology. Derived from Melanotan II through targeted structural modification, this cyclic heptapeptide selectively activates melanocortin-3 and melanocortin-4 receptors, initiating a signaling cascade that culminates in enhanced central arousal through mechanisms involving hypothalamic oxytocin release.

The FDA approval of Vyleesi in June 2019 validated decades of research into melanocortin-mediated sexual function and established a new therapeutic approach operating through central mechanisms fundamentally distinct from peripheral vasodilators. This approval represents the first melanocortin-based therapy for any clinical indication and opens potential avenues for future applications targeting this receptor family.

From a mechanistic perspective, PT-141 provides valuable insights into the integration of melanocortin signaling with broader neuroendocrine systems governing sexual behavior. The requirement for MC4R activation, the involvement of hypothalamic oxytocin pathways, and the context-dependent nature of the response all contribute to our understanding of central arousal mechanisms.

However, important distinctions exist between the approved pharmaceutical product (Vyleesi) and research-grade PT-141. The former represents a quality-controlled, regulated medication with established safety and efficacy data, while the latter exists outside regulatory frameworks and may vary in quality and purity. Researchers and readers should maintain awareness of these distinctions when evaluating the literature and considering potential applications.

The current evidence base, while robust for the approved indication, has notable limitations including restricted population studies, absence of head-to-head comparisons with alternative treatments, and incomplete understanding of long-term effects. Future research directions may address these gaps while potentially expanding our understanding of melanocortin system biology and its therapeutic potential.

For the research community, PT-141 serves as both a pharmaceutical success story and a continuing tool for investigating central nervous system regulation of sexual function, energy homeostasis, and related physiological processes. Its development from Melanotan II exemplifies rational peptide drug design and provides a template for future melanocortin-targeted therapeutic development.

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

2. Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x

3. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. doi:10.2217/whe-2016-0018

4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500

5. Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. doi:10.1097/AOG.0000000000003514

6. Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x

7. Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101

8. Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA. 2002;99(17):11381-11386. doi:10.1073/pnas.172378699

9. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62903-X

10. Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12(Suppl 4):S74-S79. doi:10.1038/sj.ijir.3900582

11. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther. 2002;28(Suppl 1):101-121. doi:10.1080/00926230252851230

12. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. 2005;76(1):1-21. doi:10.1016/j.pneurobio.2005.06.002

13. Cai M, Hruby VJ. The melanocortin receptor system: a target for multiple degenerative diseases. Curr Protein Pept Sci. 2016;17(5):488-496. doi:10.2174/1389203717666160226145330

14. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. doi:10.1016/0024-3205(96)00160-9

15. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200

16. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5(4):887-897. doi:10.1111/j.1743-6109.2007.00698.x

17. Anderson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-450.

18. U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release. June 21, 2019. Accessed March 2026.